Empire Genomics

Empire Genomics’ BDot Probe Line is expertly engineered for seamless use on the BioDot CellWriter™ S, offering a fully optimized solution for high-throughput hematology FISH testing. Each probe is prediluted, ready-to-use, and conveniently packaged in PIMS tubes to streamline workflow, reduce hands-on time, and minimize errors. With 44 probes spanning 11 critical hematologic panels—including customizable options—our BDot probes deliver consistent, high-quality results that labs can trust. Design

Discover expertly designed FISH probes tailored to specific disease areas, making it easier to move from question to assay with confidence. From leukemias and lymphomas to solid tumor applications, this library is built to help your team find the right starting point quickly.

Join our field application specialist Ashlee Dunne in our upcoming webinar on NTRK and its recent interest within the clinical and research community. During this webinar, attendees will learn more about the NTRK genes, their common fusion partners, and what one can expect to see in a normal or abnormal sample.

Paraneoplastic syndromes are rare disorders co-occurring with cancer that are not directly related to the local presence of tumor cells, but result from the generation of autoantibodies, cytokines, hormones, or peptides in response to the malignancy. These syndromes have complex manifestations that can affect multiple organ systems, including the neurological, dermatological, gastrointestinal, endocrine, hematologic, and cardiovascular systems; neurologic presentations are most common.

Non-small cell lung cancer (NSCLC) is the most common form of lung cancer and a leading cause of death worldwide. Fortunately, the survival rate for NSCLC patients has been increasing, in large part due to advances in targeted molecular and immunotherapies. Somatic mutations and gene fusions that alter the receptor tyrosine kinase (RTK)/RAS/REF pathway are frequent

Non-small-cell lung cancer (NSCLC) is a genetically heterogeneous disease. In approximately 2% of NSCLC cases, the primary oncogenic mutation is a chromosomal rearrangement involving ROS1 (ROS proto-oncogene 1), where one of many diverse gene partners fuses to the 3’ kinase domain of ROS1 and results in the constitutive activation of the ROS1 receptor tyrosine kinase. The ROS1-targeted tyrosine kinase inhibitor (TKI) entrectinib is an FDA-approved treatment for patients with these ROS1 fusions (

Endometrial polyps (EMPs) are localized overgrowths of endometrial tissue composed of endometrial glands, stroma, and blood vessels. The reported prevalence of EMPs increases with age and ranges from 8-35%, depending on the population studied. EMPs are considered benign, with a risk of malignancy of around 3%.

Biocare Medical, a leading provider of innovative, automated immunohistochemistry (IHC) and FISH (Fluorescent in situ hybridization) instrumentation and reagents, announces the acquisition of Empire Genomics, a market leader in molecular biomarkers to aid in cancer research and diagnostics.

Buffalo, New York – April 1, 2024 – Empire Genomics Corp has been awarded a national group purchasing agreement for Molecular Analyzers, Reagents with Premier, Inc. Effective 02/01/2024, the new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for FISH (Fluorescent in situ Hybridization) Probes. “Empire [...]

July 20th, Buffalo, NY – Empire Genomics, a company that develops high-quality molecular probes for fluorescent and chromogenic in situ hybridization testing, has selected Andre Lubarsky to initiate the new North American business development strategy as Director of Sales. Andre is a seasoned sales director, most recently with System Biosciences, Inc., who will now be leveraging his experience to develop and execute key growth sales strategies in the United States and North America.

FOR IMMEDIATE RELEASE Empire Genomics, a Biocare Medical Company, Partners with BioDot to Launch First Pre-Optimized Hematology FISH Probe Panels and Controls for the CellWriter™ S Platform New BDot Probe Panels Streamline and Accelerate FISH Testing for Hematologic Malignancies with Exceptional Performance and Compatibility Buffalo, NY and Irvine, CA – April 24, 2025 — Empire [...]

Every request is a priority—our specialists respond within 24 hours with a tailored quote. U.S. customers work directly with our sales team, while international customers are supported by our trusted distributor network. That’s why Empire is the First Choice in FISH.

Luis de Luzuriaga serves as the Chief Executive Officer and is a member of the Board of Directors of Biocare Medical Ltd. In this position, Mr. de Luzuriaga reports to the Board of Directors and is responsible for driving the organization to meet customer satisfaction and market growth objectives. A seasoned executive, Mr. de Luzuriaga has held senior leadership positions with Abbott, Bayer, and Leica Biosystem (A Danaher Company). Mr. de Luzuriaga is a dynamic, global leader who has successfull

Dr. Nowak is recognized as a leader in the field of human genomics. Her research contributed directly to the Human Genome Project, as well as to genomic based approaches to understanding heritable disorders and cancer. Dr. Nowak is the founder and Chief Scientific Officer of Empire Genomics. In 2015, Dr. Nowak was named executive director for the University at Buffalo (UB) New York State Center of Excellence in Bioinformatics and Life Sciences, and holds the rank of Professor of Biochemistry. Dr

As new drugs are developed that target specific gene mutations, new diagnostic tests also need to be available to determine if those drugs will have a positive outcome for a patient. At Empire Genomics, we are working with leading research and clinical institutions to bring those diagnostic tests to market faster than any other competitor. Over the past year, our access to Roswell Parks BAC library has enabled us to develop and sell highly specific tests for drugs that target NTRK for solid tumo

[wpforms id=”147498″]